|
Post by brotherm1 on Jul 9, 2019 13:01:44 GMT -5
Would it be feasible for UTHR to make Ralenipag inhalable?
|
|
|
Post by peppy on Jul 9, 2019 13:12:05 GMT -5
Would it be feasible for UTHR to make Ralenipag inhalable? I think so. www.arenapharm.com/wp-content/uploads/2016/12/Ralinepag-An-Orally-Active-Prostacyclin-Receptor-Agonist-for-the-Treatment-of-Pulmonary-Arterial-Hypertension-J-Med-Chem-2017.pdfPulmonary arterial hypertension (PAH) is a rare but life- threatening disease. The pathogenesis, which is thought to result in part from an imbalance in the production of two cyclooxygenase metabolites of arachidonic acid, prostacyclin (PGI2) and thromboxane A2,1,2 includes pulmonary vaso- constriction, endothelial and smooth muscle cell proliferation, tissue remodeling, and platelet mediated thrombosis.3 The protective effects of PGI2 arise via activation of the prostacyclin receptor (IP) which leads to stimulation of adenylate cyclase, with a resulting increase in intracellular cAMP levels, in platelets, smooth muscle cells, and immune cells. Therapeutic substitution of PGI2 or its analogues in PAH patients can reduce pulmonary artery pressure and slow disease pro- gression.4 This class of compounds generally has short half- lives in vivo due to chemical and metabolic instability and has to be dosed by repeated inhalation or continuous intravenous infusion. The larger prostanoid ligand family evokes diverse biological actions in many tissues and cell types by binding to multiple specific cell surface G-protein-coupled receptors including prostaglandin D2 receptors (DP1, DP2), prostaglandin E2 receptors (EP1, EP2, EP3, EP4), prostaglandin F2a receptor (FP), and the thromboxane receptor (TP) in addition to IP. Thus, we sought to design new prostacyclin receptor agonists with significantly improved pharmacokinetic profiles that, like selexipag, might be dosed orally but that would not require metabolic activation while staying mindful of the requirement for good receptor selectivity to avoid other prostaglandin mediated activities. Although the majority of clinical side effects of current prostacyclin agonists are thought to be on target, activation of other prostaglandin receptors, such as EP3 in the gut for example, may contribute to some of the GI symptoms observed with previous agents.
|
|
|
Post by ktim on Jul 10, 2019 11:48:29 GMT -5
Double? $76 X 2 = $152 or $1.15 X 2 = $2.30 I think that MNKD share holders will see a double a LITTLE sooner than UTHR. But, that's mytakeonit You think the next reverse split for MNKD will only be 2:1
|
|
|
Post by cretin11 on Jul 10, 2019 16:49:23 GMT -5
Yeah, MNKD might even see a QUINTUPLE (like we did on the last reverse split)!
|
|
|
Post by kite on Sept 11, 2019 5:19:55 GMT -5
ir.unither.com/news-releases/news-release-details/united-therapeutics-announces-fda-acceptance-trevyent-new-drugUnited Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020. Trevyent is a post-phase III development-stage drug-device combination product that combines two-day, single use, disposable PatchPump® technology with treprostinil, for the subcutaneous treatment of PAH.
|
|
|
Post by rockstarrick on Sept 11, 2019 5:28:23 GMT -5
ir.unither.com/news-releases/news-release-details/united-therapeutics-announces-fda-acceptance-trevyent-new-drugUnited Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020. Trevyent is a post-phase III development-stage drug-device combination product that combines two-day, single use, disposable PatchPump® technology with treprostinil, for the subcutaneous treatment of PAH. Saweet!! thanks kite, ✌🏻😎
|
|
|
Post by uvula on Sept 11, 2019 7:31:06 GMT -5
This is the noninhaled version of Trep. Not sure if this news is negative or positive for mnkd.
|
|
|
Post by cretin11 on Sept 11, 2019 7:38:00 GMT -5
This is the noninhaled version of Trep. Not sure if this news is negative or positive for mnkd. Exactly my thoughts. Hope somebody can explain how this helps us, it doesn’t look positive on its face.
|
|
|
Post by mike0475 on Sept 11, 2019 7:46:07 GMT -5
All these years and we still do not fully read
|
|
|
Post by Clement on Sept 11, 2019 7:56:49 GMT -5
Re: Trevyent New Drug Application
A good thing for UTHR -- If UTHR is healthy, then they can better pursue commitments and opportunities with MNKD.
|
|
paul
Researcher
Posts: 134
|
Post by paul on Sept 11, 2019 8:01:21 GMT -5
ir.unither.com/news-releases/news-release-details/united-therapeutics-announces-fda-acceptance-trevyent-new-drugUnited Therapeutics Announces FDA Acceptance Of Trevyent New Drug Application For Review SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Sept. 11, 2019 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for Trevyent® (treprostinil) for the treatment of pulmonary arterial hypertension (PAH). The FDA assigned the NDA a Prescription Drug User Fee Act (PDUFA) target action date of April 27, 2020. Trevyent is a post-phase III development-stage drug-device combination product that combines two-day, single use, disposable PatchPump® technology with treprostinil, for the subcutaneous treatment of PAH. For anyone interested, I posted in the other biopharma stocks section about CORV (Correvio) which holds the international license to trevyent.
|
|
|
Post by rockstarrick on Sept 11, 2019 9:50:29 GMT -5
All these years and we still do not fully read I didn’t need to read, I own both 😎
|
|
|
Post by uflawdog on Sept 11, 2019 12:27:27 GMT -5
One person's view of it: link
|
|
|
Post by mytakeonit on Sept 11, 2019 12:30:51 GMT -5
Just like a typical gun owner ... Shoots at everything moving !!!
But, that's mytakeonit
|
|
|
Post by centralcoastinvestor on Feb 24, 2020 9:34:26 GMT -5
The announcement of this expanded label is the next step in making the UTHR and MNKD relationship more valuable. It is my understanding that this expanded label allows many many more patients to use UTHR’s current treatment. Eventually, with approval of TreT, all those patients would move to TreT. Although today’s announcement is not about Mnkd, it is a direct step that ultimately helps Mnkd. finance.yahoo.com/news/united-therapeutics-deka-announce-additional-111600860.html
|
|